

Memo

To: Providers/Prescribers for Jai Medical Systems Members
From: Jai Medical Systems Managed Care Organization, Inc.
Date: November 30, 2019
Subject: Hepatitis C Treatment Prior Authorization (PA) Criteria

Maryland Medicaid has updated their PA criteria for the treatment of Hepatitis C, effective January 1, 2020. The most significant change to the criteria is that, starting January 1, 2020, there will no longer be a minimum qualifying fibrosis score for treatment, though fibrosis scoring is still required.

Additionally, Maryland Medicaid updated their criteria effective November 1, 2019, in response to the updated prescribing information for Mavyret; per the criteria, only 8 weeks of treatment is allowed for treatment naïve patients.

A copy of the criteria effective January 1, 2020 can be found on our website at <https://www.jaimedicalsystems.com/providers/pharmacy/>

A copy of the current criteria can be found online at <https://mmcp.health.maryland.gov/pap/Pages/Hepatitis-C-Therapy.aspx> or on our website at <https://www.jaimedicalsystems.com/providers/pharmacy/>.

Jai Medical Systems will continue to use the clinical criteria from Maryland Medicaid when approving all treatments. The current list of preferred treatments (prior authorization still required) for Hepatitis C remains:

generic Harvoni (ledipasvir-sofosbuvir)	Genotypes 1,4,5,6
generic Epclusa (sofosbuvir-velpatasvir)	All Genotypes
Zepatier	Genotypes 1 and 4
Mavyret	All Genotypes

Providers can contact ProCare's Prior-Authorization Department at 800-555-8513 for assistance with PA requests or questions regarding clinical guidelines. ProCare's PA Department is available Monday through Friday from 8:30 am-5:30 pm EST. For assistance with PA requests during non-business hours please contact ProCare's 24 hour customer service department at 800-213-5640.